The impact of hyperfractionated radiotherapy regimen in patients with non-small cell lung cancer

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Holgersson, Georg ^a   Bergqvist, Michael ^a   Nyman, Jan ^b   Hoye, Even ^c   Helsing, Martin ^d   Friesland, Signe ^e   Holgersson, Margareta ^a   Ekberg, Lars ^f   Mörth, Charlotte ^g   Ekman, Simon ^a   Blystad, Thomas ^h   Ewers, Sven Börje ^f   Löden, Britta ⁱ   Henriksson, Roger ^j   Bergström, Stefan ^c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c GÄVLE HOSPITAL   (Sweden)

^d ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g Malar Hospital   (Sweden)

^h LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

ⁱ CENTRAL HOSPITAL   (Sweden)

^j UMEÅ UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Hyperfractionation; Lung cancer; NSCLC; Radiotherapy; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERFRACTIONATED RADIOTHERAPY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOLOGY WARD; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; CANCER STAGING; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DOSE FRACTIONATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS;

EID: 84880581842     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0320-y     Document Type: Article

References (18)

1. Minna JD, Fong K, Zochbauer-Muller S, Gazdar AF. Molecular pathogenesis of lung cancer and potential translational applications. Cancer J. 2002;8(Suppl 1):S41-6.
2. Baujat B, Bourhis J, Blanchard P et al. Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev. 2010;12:CD002026.
3. Benschop K, Minnaar R, Koen G et al. Detection of human enterovirus and human parechovirus (HPeV) genotypes from clinical stool samples: polymerase chain reaction and direct molecular typing, culture characteristics, and serotyping. Diagn Microbiol Infect Dis. 2010;682:166-73.
4. Free CM, Ellis M, Beggs L, Beggs D, Morgan SA, Baldwin DR. Lung cancer outcomes at a UK cancer unit between 1998-2001. Lung Cancer. 2007;572:222-8.
5. Bonomi M, Blanco-Savorio A, Cerchietti L, et al. Continuous hyperfractionated accelerated radiation therapy week-end less in combination with neoadjuvant chemotherapy for the treatment of stage III non-small-cell lung cancer. Lung Cancer. 2008;601:75-82.
6. Perez CA, Stanley K, Rubin P, et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the radiation therapy oncology group. Cancer. 1980;4511:2744-53.
7. Baumann M, Appold S, Petersen C, Zips D, Herrmann T. Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer. Lung Cancer. 2001;33(Suppl 1):S35-45.
8. Arriagada R, Komaki R, Cox JD. Radiation dose escalation in non-small cell carcinoma of the lung. Semin Radiat Oncol. 2004;144:287-91.
9. Saunders MI. Programming of radiotherapy in the treatment of non-small-cell lung cancer - a way to advance care. Lancet Oncol. 2001;27:401-8.
10. Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol. 1999;522:137-48.
11. Kagami Y, Nishio M, Narimatsu N, Ogawa H, Sakurai T. Prospective randomized trials comparing hyperfractionated radiotherapy with conventional radiotherapy in stage III non-small cell lung cancer. Nihon Igaku Hoshasen Gakkai Zasshi. 1992;5210:1452-5.
12. Fu S, Jiang GL, Wang LJ. Hyperfractionated irradiation for non-small cell lung cancer (NSCLC) - a phase III clinical trial. Zhonghua Zhong Liu Za Zhi. 1994;164:306-9.
13. Sause W, Kolesar P, Taylor SI, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: radiation therapy oncology group, eastern cooperative oncology group, and southwest oncology group. Chest. 2000;1172:358-64.
14. Baumann M, Herrmann T, Koch R et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol. 2011;1001:76-85.
15. Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering committee. Lancet. 1997;3509072:161-5.
16. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol. 2000;187:1458-64.
17. Saunders KJ, Spradlin JE. Conditional discrimination in mentally retarded subjects: programming acquisition and learning set. J Exp Anal Behav. 1993;603:571-85.
18. Belani CP, Wang W, Johnson DH, et al. Phase III study of the eastern cooperative oncology group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol. 2005;2316:3760-7.